1. Lieven A, Francis A, Olivier B, Kris B, Bogaert M, Stefaan C, et al. A call to make valuable innovative medicines accessible in the European Union. 2010. http://www.reesfrance.com/en/IMG/pdf/PlenaryII-Making-Innovative-Medicine-Accessible-in-the-EU.pdf. Accessed 2 May 2019.
2. INAMI. Outcomes based pricing and reimbursement of innovative medicines with budgetary limitations: discussion document for the multistakeholders meeting on pharmaceuticals (12th September 2017). https://www.inami.fgov.be/SiteCollectionDocuments/innovative_medicines_with_budgetary_limitations.docx. Accessed 9 Jul 2020.
3. UN. Sustainable Development Goal 3: ensure healthy lives and promote well-being for all at all ages. 2019. https://sustainabledevelopment.un.org/sdg3. Accessed 9 Jul 2020.
4. Morton S, Pencheon D, Squires N. Sustainable Development Goals (SDGs), and their implementation: a national global framework for health, development and equity needs a systems approach at every level. Br Med Bull. 2017;124(1):81–90.
5. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1. Accessed 9 Jul 2020.